ClinicalTrials.Veeva

Menu

Neurogenic Mechanisms in Burning Mouth Syndrome (BMS17)

University of Copenhagen logo

University of Copenhagen

Status

Completed

Conditions

Burning Mouth Syndrome

Treatments

Other: Capsaicin oral gel 0.01%
Other: Capsaicin oral gel 0.025%

Study type

Interventional

Funder types

Other

Identifiers

NCT00875537
H-A-2008-118

Details and patient eligibility

About

Burning mouth syndrome (BMS) is characterized by a bilateral burning sensation in the anterior tongue, hard palate and lips in the absence of any clinical or laboratory findings. The term syndrome implicates the simultaneous presence of oral dryness (xerostomia) and altered taste (dysgeusia) in addition to the burning sensation in the oral mucosa. BMS is most often seen in women and is more frequent during menopause. The etiology and pathogenesis are still unclear but recent studies suggest that BMS is a neuropathic pain condition.

The objectives of the study are:

  • To clarify potential neurogenic mechanisms behind BMS using immunohistochemistry (IH) to characterize the localization and distribution of peripheral nerve fibres, neuropeptides like substance P, calcitonin gene-related peptide, nerve growth factor, nerve growth factor receptor, PGP 9.5 neuronal marker and TRPV1 as well as inflammatory/structural changes.
  • To perform a randomized double blind cross-over intervention study to examine the efficacy and safety of topical application of capsaicin oral gel (on the tongue) to relieve the burning sensation in patients with BMS.

Full description

Data which support the hypothesis that BMS is a neuropathic pain condition include amongst others a recent clinically controlled study that has shown up-regulation of TRPV1-positive nerve fibres in tongue mucosa in patients with BMS. The vanilloid receptor-1 (TRPV1) is a voltage-dependent cation channel expressed by the unmyelinated C-nociceptive nerve fibres and the receptor may be activated by capsaicin (from chili peppers), heat and H+. Capsaicin binds to the TRPV1 receptor causing depolarization of the C-nociceptors. Prolonged activation of these neurons by capsaicin depletes pre-synaptic substance P and makes them unable to report pain.

Enrollment

22 patients

Sex

Female

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • non-smoking female patients with burning mouth syndrome (n=26)
  • healthy aged-matched control group (n=10)

Exclusion criteria

  • pregnancy and lactation (inclusion requires negative pregnancy test)
  • women who do not use safe anticonception
  • patients with know allergy/hypersensitivity to capsicum and other capsaicinoid-containing products
  • Active infection which requires antibiotic treatment
  • use of mouthrinse. The use of these is stopped 14 days before inclusion
  • patients who are able to give informed consent due to physical or mental disabilities

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

22 participants in 2 patient groups

Capsaicin oral gel 0.01%
Active Comparator group
Treatment:
Other: Capsaicin oral gel 0.01%
Capsaicin oral gel 0.025%
Active Comparator group
Treatment:
Other: Capsaicin oral gel 0.025%

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems